Moderna shares fall after judge sides with Arbutus in patent fight
Reprints
(Reuters) — Shares of Moderna fell 4% on Wednesday after a U.S. judge issued an order that strengthened Arbutus’ arguments in a patent infringement lawsuit related to Moderna’s blockbuster COVID-19 vaccines.
Roivant’s shares gained 4% in afternoon trading, while its subsidiary Arbutus rose more than 17%.
In a so-called “claim construction order,” U.S. District Judge Mitchell Goldberg interpreted parts of the patents in ways that strengthened Arbutus’ case, rejecting Moderna’s proposed definitions.
The order is relevant in determining whether Moderna’s vaccines are covered by Arbutus’ patented technology.
